TrialJournal of hematology & oncology2021

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.

Huiqiang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.